Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9%

NACompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Catheter Related Blood Stream Infections
Interventions
DEVICE

TauroSept®

"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."

Trial Locations (7)

2100

University Hospital Copenhagen Rigshospitalet, Copenhagen

40138

University of Bologna Center for Chronic Intestinal Failure Department of Gastroenterology and Internal Medicine, Bologna

48149

University Clinic Münster, Münster

49100

Rabin Medical Center, Petah Tikva

6500 HB

Department of Gastroenterology and Hepatology clinical ward, Nijmegen

HA1 3UJ

St Mark's Hospital, Harrow

NW1 2PG

University College Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Geistlich Pharma AG

INDUSTRY

lead

Geert Wanten

OTHER

NCT01826526 - Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9% | Biotech Hunter | Biotech Hunter